top of page

SynaptixBio reaches hugely significant milestone with selection of candidate drug for clinical trials

Dr Dan Williams
Jul 8
1 min read

SynaptixBio selects H -ABC antisense oligonucleotide for progression to clinical trials - read about it here >

SynaptixBio select candidate drug for clinical trials

Recent Posts

Drug Target Review features an insightful article by Dan Williams that explores the extraordinary achievements of AI in drug design

Drug Target Review features an insightful article by Dan Williams that explores the extraordinary achievements of AI in drug design

Dr Uwe Meya, SynaptixBio’s CMO

Technology Networks features a major interview with Dr Uwe Meya, SynaptixBio’s CMO, in which the issues around organising, funding, and conducting clinical trials for rare diseases are discussed.

Dan Williams contributes to a major article for Inside Precision Medicine, in which several US families with a child living with H-ABC discuss their journey to a diagnosis

Dan Williams contributes to a major article for Inside Precision Medicine, in which several US families with a child living with H-ABC discuss their journey to a diagnosis

bottom of page